Mark J. Pykett
2012
In 2012, Mark J. Pykett earned a total compensation of $1.9M as Chief Executive Officer at Navidea Biopharmaceuticals, a 161% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $140,250 |
|---|---|
| Option Awards | $385,462 |
| Salary | $425,000 |
| Stock Awards | $983,700 |
| Other | $13,808 |
| Total | $1,948,220 |
Pykett received $983.7K in stock awards, accounting for 50% of the total pay in 2012.
Pykett also received $140.3K in non-equity incentive plan, $385.5K in option awards, $425K in salary and $13.8K in other compensation.
Rankings
In 2012, Mark J. Pykett's compensation ranked 3,651st out of 11,487 executives tracked by ExecPay. In other words, Pykett earned more than 68.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,651 out of 11,487 | 68th |
Division Manufacturing | 1,253 out of 4,253 | 71st |
Major group Chemicals And Allied Products | 282 out of 1,203 | 77th |
Industry group Drugs | 164 out of 925 | 82nd |
Industry In Vitro and In Vivo Diagnostic Substances | 6 out of 47 | 87th |
Source: SEC filing on June 5, 2015.
Pykett's colleagues
We found four more compensation records of executives who worked with Mark J. Pykett at Navidea Biopharmaceuticals in 2012.
2012
Thomas Tulip
Navidea Biopharmaceuticals
President and Chief Business Officer
2012
Frederick Cope
Navidea Biopharmaceuticals
Chief Scientific Officer
2012
Brent Larson
Navidea Biopharmaceuticals
Chief Financial Officer
2012
Rodger Brown
Navidea Biopharmaceuticals